Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Federico II University |
---|---|
Information provided by: | Federico II University |
ClinicalTrials.gov Identifier: | NCT00699023 |
The purpose of this study is to determine whether ezetimibe in association with statins is more effective than statins alone on postprandial lipemia in type 2 diabetic patients.
Condition | Intervention | Phase |
---|---|---|
Postprandial Lipemia Type 2 Diabetes |
Drug: ezetimibe tablets Drug: simvastatin tablets Drug: placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Crossover Assignment, Efficacy Study |
Official Title: | Effects of Ezetimibe in Association With Statins on Postprandial Lipemia in Type 2 Diabetic Patients |
Estimated Enrollment: | 13 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
ezetimibe tablets 10 mg/die + simvastatin tablets 20 mg/die six weeks
|
Drug: ezetimibe tablets
ezetimibe tablets 10 mg/die
Drug: simvastatin tablets
simvastatin tablets 20 mg/die
|
2: Placebo Comparator
placebo + simvastatin tablets 20 mg/die six weeks
|
Drug: simvastatin tablets
simvastatin tablets 20 mg/die
Drug: placebo
placebo
|
Ages Eligible for Study: | 40 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Italy | |
Department of Clinical and Experimental Medicine, Federico II University Hospital, | |
Naples, Italy, 80131 |
Study Chair: | Gabriele Riccardi, Prof | Department of Clinical and Experimental Medicine, Federico II University Hospital, Naples, Italy |
Responsible Party: | Department of Clinical and Experimental Medicine Federico II University Naples ( Angela A. Rivellese, MD ) |
Study ID Numbers: | 239/07 |
Study First Received: | June 13, 2008 |
Last Updated: | July 1, 2009 |
ClinicalTrials.gov Identifier: | NCT00699023 History of Changes |
Health Authority: | Italy: Ethics Committee |
postprandial lipemia type 2 diabetes ezetimibe hypercholesterolemia |
Antimetabolites Hyperlipidemias Metabolic Diseases Simvastatin Antilipemic Agents Diabetes Mellitus Endocrine System Diseases Ezetimibe Anticholesteremic Agents |
Hydroxymethylglutaryl-CoA Reductase Inhibitors Diabetes Mellitus, Type 2 Endocrinopathy Glucose Metabolism Disorders Hypercholesterolemia Metabolic Disorder Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Hyperlipidemias Metabolic Diseases Molecular Mechanisms of Pharmacological Action Simvastatin Antilipemic Agents Diabetes Mellitus Endocrine System Diseases Enzyme Inhibitors |
Ezetimibe Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Therapeutic Uses Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Dyslipidemias Lipid Metabolism Disorders |